Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101

"In Part A, participants will receive single dose of LYN101 administered as a subcutaneous (SC) injection.~In Part B, participants will receive multiple doses of LYN101 administered as a SC injection."

"In Part A, participants will receive single dose of the matched placebo administered as a subcutaneous (SC) injection (4 cohorts).~In Part B, participants will receive multiple doses of the matched placebo administered as a SC injection."